No headlines found.
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Sat, 6-Apr 1:05 AM ET)
Curis to Present at Upcoming Healthcare Conferences in April
PRNewswire (Sat, 6-Apr 12:56 AM ET)
PRNewswire (Tue, 2-Apr 9:15 AM ET)
Curis Provides Fourth Quarter 2023 Business Update
PRNewswire (Thu, 8-Feb 8:00 AM ET)
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
PRNewswire (Thu, 1-Feb 8:00 AM ET)
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis trades on the NASDAQ stock market under the symbol CRIS.
As of April 19, 2024, CRIS stock price declined to $14.31 with 10,123 million shares trading.
CRIS has a beta of 2.89, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.10 to the broad based SPY ETF.
CRIS has a market cap of $84.34 million. This is considered a Micro Cap stock.
Last quarter Curis reported $3 million in Revenue and -$2.03 earnings per share. This fell short of revenue expectation by $-324,000 and exceeded earnings estimates by $.08.
In the last 3 years, CRIS stock traded as high as $348.00 and as low as $3.80.
The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF, DFUS, DFAC, AVSC.
CRIS has underperformed the market in the last year with a price return of -25.6% while the SPY ETF gained +21.2%. However, in the short term, CRIS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +16.9% vs +4.3% return in SPY. But in the last 2 weeks, CRIS shares have been beat by the market, returning -10.6% compared to an SPY return of -3.5%.
CRIS support price is $14.12 and resistance is $16.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS stock will trade within this expected range on the day.